Play a Major Role in Defining Long-Term Survival, Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities, vol.30, pp.1949-52, 2012. ,
, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012: étude à partir des registres des cancers du réseau Francim, 2013.
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ?, Ann Oncol. 1 juill, vol.28, issue.suppl_4, pp.52-61, 2017. ,
International Staging System for Multiple Myeloma, J Clin Oncol. 20 mai, vol.23, issue.15, pp.3412-3432, 2005. ,
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J Clin Oncol. 10 sept, vol.33, issue.26, pp.2863-2872, 2015. ,
DOI : 10.1200/jco.2015.61.2267
URL : http://europepmc.org/articles/pmc4846284?pdf=render
Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Ann Biol Clin, issue.5, pp.588-595 ,
Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy, Biol Blood Marrow Transplant. avr, vol.16, issue.4, pp.548-54, 2010. ,
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation, Leuk Lymphoma. 3 août, vol.58, issue.8, pp.1823-1854, 2017. ,
+1q: amplifying the bad genes in myeloma, Leuk Lymphoma. 3 août, vol.58, issue.8, pp.1771-1774, 2017. ,
DOI : 10.1080/10428194.2016.1272689
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance, Oncotarget, vol.1, issue.1, 2010. ,
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside, Am Soc Clin Oncol Educ Book. 23 mai, issue.38, pp.675-80, 2018. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, issue.12, pp.538-586, 2014. ,
A high-risk, DoubleHit, group of newly diagnosed myeloma identified by genomic analysis, Leukemia, issue.2, 2018. ,
,
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21, Eur J Haematol. janv, vol.96, issue.1, pp.46-54, 2016. ,
DOI : 10.1111/ejh.12546
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma, vol.51, pp.2084-91, 2010. ,
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma: Molecular Approach to Dectect Copy Number Abnormalities in Myeloma, Genes Chromosomes Cancer. févr, vol.54, issue.2, pp.91-99, 2015. ,
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival, Clin Cancer Res. 15 déc, vol.17, issue.24, pp.7776-84, 2011. ,
Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens: Gain of Chromosome 1 in Multiple Myeloma, Am J Hematol. juin, vol.89, issue.6, pp.616-636, 2014. ,
Cytogenetic and clinical marks for defining highrisk myeloma in the context of bortezomib treatment, Exp Hematol. mars, vol.43, issue.3, pp.168-176, 2015. ,
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients, Leukemia. mars, vol.28, issue.3, pp.675-684, 2014. ,
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience, Blood. 26 mars, vol.125, issue.13, pp.2095-100, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01818052
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma, Hematology. sept, vol.10, issue.sup1, pp.117-143, 2005. ,
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma, Leukemia. nov, vol.20, issue.11, pp.2034-2074, 2006. ,
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies, Haematologica, vol.99, issue.10, pp.1611-1618, 2014. ,
DOI : 10.3324/haematol.2014.103853
URL : http://www.haematologica.org/content/99/10/1611.full.pdf
CKS1B/CDKN2C (P18) amplification/deletion as prognostic markers in multiple myeloma patients, Egypt J Haematol, vol.41, issue.2, p.87, 2016. ,
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group, Blood. 16 juin, vol.127, issue.24, pp.2955-62, 2016. ,